Discontinued — last reported Q1 '26
Prevymis — Sales
Merck & Co. Prevymis — Sales decreased by 50.7% to $272.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.6%, from $416.00M to $272.00M. Over 4 years (FY 2021 to FY 2025), Prevymis — Sales shows an upward trend with a 27.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in sales indicates successful market penetration, expanded clinical adoption, or increased patient demand for CMV prophylaxis, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total annual revenue generated from the sale of a specific antiviral medication used for the...
Peer comparison
Comparable to specialized therapeutic product revenue lines at other pharmaceutical companies, often benchmarked against similar niche antiviral or transplant-related drug portfolios.
mrk_segment_prevymis_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $186.00M | $192.00M | $199.00M | $188.00M | $206.00M | $227.00M | $235.00M | $258.00M | $286.00M | $314.00M | $352.00M | $348.00M | $376.00M | $416.00M | $430.00M | $416.00M | $456.00M | $532.00M | $552.00M | $272.00M |
| QoQ Change | — | +3.2% | +3.6% | -5.5% | +9.6% | +10.2% | +3.5% | +9.8% | +10.9% | +9.8% | +12.1% | -1.1% | +8.0% | +10.6% | +3.4% | -3.3% | +9.6% | +16.7% | +3.8% | -50.7% |
| YoY Change | — | — | — | — | +10.8% | +18.2% | +18.1% | +37.2% | +38.8% | +38.3% | +49.8% | +34.9% | +31.5% | +32.5% | +22.2% | +19.5% | +21.3% | +27.9% | +28.4% | -34.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s prevymis — sales?
- Merck & Co. (MRK) reported prevymis — sales of $272.00M in Q1 2026.
- How has Merck & Co.'s prevymis — sales changed year-over-year?
- Merck & Co.'s prevymis — sales decreased by 34.6% year-over-year, from $416.00M to $272.00M.
- What is the long-term trend for Merck & Co.'s prevymis — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s prevymis — sales has grown at a 27.5% compound annual growth rate (CAGR), from $741.00M to $1.96B.
- What does prevymis — sales mean?
- The total annual revenue generated from the sales of the Prevymis antiviral medication.